A CONSISTENT AND TOLERABLE

SAFETY PROFILE1

MOST ADVERSE EVENTS in ALINA WERE MILD-TO-MODERATE (Grades 1–2)1

ALINA: Adverse events occurring in ≥15% of patients2

alina-chart.png

ALINA: Adverse events occurring in ≥15% of patients2

Figureredraw-mobile300ppi.png

The safety profile of ALECENSA in resected ALK+ NSCLC was consistent with the established ALECENSA safety profile1,3–5

  • Treatment withdrawal due to adverse events occurred in 5.5% of patients on ALECENSA vs 12.5% of patients on chemotherapy1

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*The safety-evaluable population included patients who underwent randomisation and received any amount of ALECENSA or platinum-based chemotherapy. AEs are listed according to Medical Dictionary for Regulatory Activities preferred term.1 Multiple occurrences of the same AE in an individual patient are counted only once.1

 

AE: adverse event; ALK: anaplastic lymphoma kinase; COVID-19: coronavirus disease 2019; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics.


1. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 2. Solomon BJ, et al. Presented at the European Society for Medical Oncology Congress, 20–24 October 2023, Madrid, Spain; 3. Hida T, et al. Lancet 2017;390(10089):29–39; 4. Peters S, et al. N Engl J Med 2017;377(9):829–838; 5. Zhou C, et al. Lancet Respir Med 2019;7(5):437–446.